As drug development programs continue to expand into more complex therapeutic modalities and patient-centric clinical trial designs, bioanalytical laboratories are under increasing pressure to generate high-quality data from smaller, less invasive samples. Volumetric absorptive microsampling (VAMS) has emerged as a promising solution, offering a practical alternative to traditional blood collection methods while supporting reliable quantitative bioanalysis.

By combining low-volume blood collection with streamlined sample handling, VAMS is helping reshape how whole blood samples are collected, processed, and analyzed across clinical and preclinical studies.

What Is Volumetric Absorptive Microsampling?

Volumetric absorptive microsampling is a technique designed to collect precise, small volumes of blood using an absorptive sampling tip. Unlike conventional venipuncture, which often requires milliliter-scale blood draws, VAMS typically collects microliter quantities of blood in a minimally invasive manner.

VAMS belongs to a broader category of microsampling technologies that includes dried blood spot (DBS) cards, capillary microfluidic devices, and wearable collection systems. However, VAMS offers several operational advantages by enabling more consistent volumetric collection and simplified sample handling workflows.

Why Microsampling Is Gaining Momentum

Traditional blood collection approaches can create logistical and operational challenges during clinical studies, especially in vulnerable patient populations or decentralized trial settings. Microsampling technologies are increasingly being adopted to help address these limitations.

Key benefits of VAMS include:

  • Lower blood volume requirements
  • Reduced patient burden
  • Minimally invasive collection procedures
  • Improved accessibility for pediatric and elderly populations
  • Expanded opportunities for pharmacokinetic sampling
  • Simplified storage and transportation logistics
  • Greater flexibility for remote or decentralized clinical studies

These advantages make microsampling particularly attractive for studies requiring frequent sampling or limited sample availability.

The Bioanalytical Challenges Behind Microsampling

Although microsampling offers meaningful operational benefits, implementing a robust quantitative assay using VAMS requires careful method development and optimization. Whole blood is a complex matrix, and low sample volumes can magnify variability if assay conditions are not properly controlled.

Several critical factors influence assay performance in VAMS workflows:

Representative Calibration and Quality Control Samples

One of the most important considerations in microsampling assay development is ensuring that calibration standards and quality control (QC) samples closely mimic study samples. Differences in matrix composition or preparation methods can introduce variability and impact quantitative accuracy.

Developing representative calibrators and QCs is essential for maintaining assay consistency and improving confidence in bioanalytical results.

Sample Drying Conditions Matter

Drying is a fundamental step in VAMS workflows because incomplete or inconsistent drying can affect analyte recovery and stability. Proper drying conditions help stabilize analytes within the microsample and support reproducible extraction performance.

Optimized drying procedures are particularly important when handling sensitive analytes or implementing workflows across multiple analysts and study sites.

Managing Dilutional Linearity and High-Concentration Samples

Quantitative ligand binding assays and other bioanalytical methods must often accommodate samples with widely varying analyte concentrations. Dilutional linearity evaluations help confirm that high-concentration samples can be accurately diluted into the assay range without compromising performance.

Microsampling workflows must also account for potential prozone effects, where extremely high analyte concentrations interfere with accurate signal generation. Evaluating dilution strategies early in assay development helps ensure reliable quantitation across the intended analytical range.

Stability and Selectivity Remain Critical

As with any regulated bioanalytical method, demonstrating analyte stability and assay selectivity is essential for successful implementation.

Microsampling assays must demonstrate that analytes remain stable during drying, storage, extraction, and freeze-thaw handling conditions. At the same time, the assay must maintain specificity in the presence of endogenous whole blood components and potential matrix interferences.

These evaluations are especially important in low-volume workflows where matrix effects may become more pronounced.

The Future of Patient-Centric Bioanalysis

The continued growth of decentralized clinical trials and precision medicine initiatives is accelerating interest in patient-friendly sample collection approaches. Microsampling technologies like VAMS align closely with these trends by enabling lower-volume, less invasive collection strategies that can support both operational efficiency and patient convenience.

For bioanalytical laboratories, VAMS also presents opportunities to improve workflow flexibility while maintaining the analytical rigor required for quantitative studies.

As the industry continues to pursue more efficient and accessible clinical research models, volumetric absorptive microsampling is positioned to become an increasingly important tool in modern whole blood bioanalysis.